• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    NanoVibronix Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    3/12/25 4:05:16 PM ET
    $NAOV
    Industrial Specialties
    Health Care
    Get the next $NAOV alert in real time by email
    false --12-31 0001326706 0001326706 2025-03-12 2025-03-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): March 12, 2025

     

    NanoVibronix, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-36445   01-0801232

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    969 Pruitt Ave

    Tyler, Texas

      77569
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (914) 233-3004

     

     
    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   NAOV   Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 3.03. Material Modification to Rights of Security Holders.

     

    To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this report is incorporated herein by reference.

     

    Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    On March 12, 2025, NanoVibronix, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) with the Secretary of State of Delaware to effect a 1-for-11 reverse stock split of the shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), either issued and outstanding or held by the Company as treasury stock, effective as of 4:05 p.m. (Delaware time) on March 13, 2025 (the “Reverse Stock Split”). As previously reported, the Company held a special meeting of stockholders on February 24, 2025 (the “Special Meeting”), at which Special Meeting the Company’s stockholders approved the Certificate of Amendment to effect a reverse stock split of the Company’s Common Stock at a ratio in the range of 1-for-2 to 1-for-11, with such ratio to be determined by the Company’s Board of Directors (the “Board”) and included in a public announcement. The Board determined to effect the Reverse Stock Split at a ratio of 1-for-11 and approved the corresponding final form of the Certificate of Amendment.

     

    As a result of the Reverse Stock Split, every eleven (11) shares of issued and outstanding Common Stock will be automatically combined into one (1) issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares will be issued as a result of the Reverse Stock Split. Any fractional shares that would otherwise have resulted from the Reverse Stock Split will be rounded up to the next whole number. The Reverse Stock Split will reduce the number of shares of Common Stock outstanding from 8,716,327 shares to approximately 792,394 shares, subject to adjustment for the rounding up of fractional shares. The number of authorized shares of Common Stock under the Certificate of Incorporation will remain unchanged at 40,000,000 shares.

     

    Proportionate adjustments will be made to the per share exercise price and the number of shares of Common Stock that may be purchased upon the exercise or conversion, as applicable, of outstanding equity awards under the Company’s 2024 Long-Term Incentive Plan (the “2024 Plan”) and the 2014 Long-Term Incentive Plan (the “2014 Plan”). The number of shares reserved for issuance under the 2024 Plan will be proportionately reduced in accordance with the terms of such plans.

     

    The Common Stock will begin trading on a Reverse Stock Split-adjusted basis on the Nasdaq Capital Market on March 14, 2025. The trading symbol for the Common Stock will remain “NAOV.” The new CUSIP number for the Common Stock following the Reverse Stock Split is 63008J702.

     

    For more information about the Reverse Stock Split, see the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on January 27, 2025, the relevant portions of which are incorporated herein by reference. The information set forth herein is qualified in its entirety by reference to the complete text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Item 8.01. Other Events.

     

    On March 12, 2025, the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    3.1   Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of NanoVibronix, Inc.
    99.1   Press Release, issued on March 12, 2025.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      NanoVibronix, Inc.
         
    Date: March 12, 2025 By: /s/ Stephen Brown
      Name: Stephen Brown
      Title: Chief Financial Officer

     

     

     

    Get the next $NAOV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NAOV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NAOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Murphy Brian M

      4 - NanoVibronix, Inc. (0001326706) (Issuer)

      1/3/25 4:05:16 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Mika Thomas

      4 - NanoVibronix, Inc. (0001326706) (Issuer)

      1/2/25 9:26:30 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Brown Stephen Russell

      4 - NanoVibronix, Inc. (0001326706) (Issuer)

      1/2/25 9:25:07 PM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Leadership Updates

    Live Leadership Updates

    See more
    • NanoVibronix Announces Results of Annual Meeting of Stockholders Held Today

      NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, announced that the Company's 2022 annual meeting of stockholders (the "Annual Meeting") was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2022. The following resolutions submitted for stockholder approval were adopted: Election of the eight director nominees (Aurora Cassirer, Christopher Fashek, Michael Ferguson, Martin Goldstein, M.D., Harold Jacob, M.D., Thomas Mika, Brian Murphy, and Maria Schroeder) to serve on the Company's board of directors (the "Board"), for a term of on

      12/15/22 4:05:00 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • NanoVibronix Reports First Quarter 2022 Financial Results

      Expanded Distribution, Entry into New Geographic Markets and Regulatory Approvals Advancing Efforts Towards Full Commercialization NanoVibronix, Inc., (NASDAQ:NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today reported its financial results for the quarter ended March 31, 2022. First Quarter 2022 Financial and Recent Business Highlights Revenue of $272,000, an increase of 164% compared to the prior year period Significant backlog of orders to be filled in Q2 Supply chain challenges are expected to abate moving into the second half of 2022 Submitted a 510(k) application to the U.S. Food and Dr

      5/17/22 8:30:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care
    • Cerro de Pasco Announces MCTO and New Chief Financial Officer

      MONTREAL, April 29, 2022 /CNW Telbec/ - Cerro de Pasco Resources Inc. (CSE:CDPR) (Frankfurt: N8HP) ("CDPR" or the "Company") announces that it has applied to the Autorité des marchés financiers (Québec) (the "AMF"), as principal regulator of the Company, and expects to be granted a management cease trade order (the "MCTO") on May 2, 2022, pursuant to Policy Statement 12-203 Respecting Management Cease Trade Orders ("PS 12-203"). Under the MCTO, the Company's Chief Executive Officer (CEO), Chief Financial Officer (CFO) and directors may not trade in securities of the Company until such time as the Company files its audited consolidated financial statements, its management's discussion and ana

      4/29/22 3:28:00 PM ET
      $GMBL
      $NAOV
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
      Industrial Specialties
      Health Care

    $NAOV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NanoVibronix Regains Nasdaq Compliance

      NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company" or "NanoVibronix"), a medical technology company specializing in non-invasive therapeutic devices, today announced that on April 9, 2025, Nasdaq formally notified the Company that it has evidenced full compliance with all criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price and $2.5 million stockholders' equity requirements. Accordingly, the previously disclosed Nasdaq listing matter has been closed. Pursuant to Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor until April 9, 2026. About NanoVibronix, Inc. NanoVibronix, Inc. (NASDAQ:NAOV) is a medical device company hea

      4/11/25 8:00:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care
    • NanoVibronix Announces Renewal and Expansion of Distribution Agreement with Dukehill Healthcare Pty Ltd in Australia

      Publication of Independent Study Heightens Demand for UroShield NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company" or "NanoVibronix"), a medical technology company specializing in non-invasive therapeutic devices, today announced the renewal and expansion of its exclusive three-year distribution agreement with Dukehill Healthcare Pty Ltd. ("Dukehill"). Dukehill, with its Head Office in Queensland, has primarily focused its clinical projects and sales efforts within the state and in New South Wales. However, the recent expansion of the agreement with the Company now extends across all Australian States, with notable growth in South Australia and Victoria. This surge follows an increasing numb

      4/1/25 8:00:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care
    • Successful Independent Study of the NanoVibronix UroShield® Device Published in the Australian and New Zealand Continence Journal

      UroShield Cited as Effective in Preventing CAUTIs and Blockages, Having a Major Impact on Quality of Life and Reducing Healthcare Resource Costs NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical technology company specializing in non-invasive therapeutic devices, today announced that an independent health service study of its UroShield® is published in The Australian and New Zealand Continence Journal. The study highlights UroShield's effectiveness in preventing catheter-associated urinary tract infections (CAUTIs) and recommends its adoption for appropriate patients with indwelling urinary catheters (IUCs). Researchers found that patients using UroShield experienced an 86% redu

      3/14/25 8:00:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    SEC Filings

    See more
    • Amendment: SEC Form S-1/A filed by NanoVibronix Inc.

      S-1/A - NanoVibronix, Inc. (0001326706) (Filer)

      4/29/25 5:30:36 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • Amendment: SEC Form S-1/A filed by NanoVibronix Inc.

      S-1/A - NanoVibronix, Inc. (0001326706) (Filer)

      4/22/25 5:24:40 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • NanoVibronix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

      8-K - NanoVibronix, Inc. (0001326706) (Filer)

      4/11/25 8:00:30 AM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

      SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

      11/14/24 5:17:34 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by NanoVibronix Inc.

      SC 13G - NanoVibronix, Inc. (0001326706) (Subject)

      2/14/24 3:45:41 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

      2/16/21 3:49:24 PM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Financials

    Live finance-specific insights

    See more
    • NanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common Stock

      NanoVibronix, Inc. (NASDAQ:NAOV) ("Nano" or the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on October 14, 2022. The shares of Series F Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on October 17, 2022. The outstanding shares of Series F Preferred Stock will vote together with the outstanding sh

      9/14/22 9:25:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care